Zhejiang Xianju Pharmaceutical (002332.SZ): Progesterone vaginal tablets have received acceptance of the registration application from the U.S. FDA.

Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company submitted an ANDA registration application for progesterone vaginal tablets to the U.S. Food and Drug Administration (referred to as "FDA"). The company recently received a notification from the FDA regarding the acceptance of the registration application. The indication for progesterone vaginal tablets is for luteal support in assisted reproductive technology (ART), which supports embryo implantation and early pregnancy by supplementing luteal function.